AVIEW LCS vs Viz RV/LV

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 55/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Coreline Soft
VS
by Viz.ai

AI Verdict

Both AVIEW LCS and Viz RV/LV utilize AI for cardiac and pulmonary imaging analysis, making them adjacent in the healthcare AI landscape. AVIEW LCS focuses on comprehensive lung nodule detection, COPD, and coronary artery calcification, suitable for general thoracic imaging workflows. Viz RV/LV, however, specializes in rapid pulmonary embolism risk stratification through automated RV/LV ratio measurements, making it more targeted for acute care settings and pulmonary embolism protocols.

Choose AVIEW LCS if…

Choose AVIEW LCS if your primary need is comprehensive AI-powered analysis of lung nodules, COPD, and coronary artery calcification from a single low-dose CT scan, aiming to enhance diagnostic accuracy and streamline radiology workflows. It is particularly well-suited for lung cancer screening programs, providing automated nodule detection, Lung-RADS classification, volume quantification, and automated comparison of nodules in follow-up scans.

View AVIEW LCS →

Choose Viz RV/LV if…

Choose Viz RV/LV if your focus is on rapid and automated risk stratification for pulmonary embolism (PE) using AI to measure right and left ventricular diameters from CTPA scans. This tool is ideal for emergency medicine and pulmonology settings where quick assessment of PE severity and enhanced care coordination are critical.

View Viz RV/LV →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature AVIEW LCS Viz RV/LV
Pricing Subscription or one-off payment Unknown
Deployment Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) Cloud-based
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AVIEW LCS

AVIEW LCS emphasizes a user-friendly viewer with advanced 3D rendering for both medical professionals and patients, aiming to provide more intuitive and informative visuals than 2D images. It also focuses on optimizing UI/UX and strengthening communication functions, suggesting a strong emphasis on user experience. Viz RV/LV provides annotated images and a summary report, but its primary focus appears to be on automated measurements and alerts rather than comprehensive visualization tools for user interaction.

Clinical Value

AVIEW LCS

AVIEW LCS offers a broader range of clinical applications by detecting and analyzing lung nodules, COPD, and coronary artery calcification from a single CT scan, providing comprehensive reports and follow-up capabilities. It has demonstrated high sensitivity and specificity in clinical trials for nodule detection and has been adopted in large-scale lung cancer screening projects. Viz RV/LV, while crucial for pulmonary embolism risk stratification, is more narrowly focused on automated RV/LV ratio measurements.

Pricing & Value

Tie

Both tools offer subscription or one-off payment models, with pricing based on installations or users for AVIEW LCS. Neither tool provides transparent pricing details publicly, making a direct comparison of value difficult. Without specific cost information or detailed ROI studies for both, it's challenging to declare a definitive winner in this dimension.

Enterprise Readiness

AVIEW LCS

AVIEW LCS offers flexible deployment options including cloud-based, hybrid, and on-premise solutions (dedicated hardware, virtualized), making it adaptable to various IT infrastructures. It also integrates with PACS/RIS and third-party platforms. Viz RV/LV is cloud-based, which can be advantageous for scalability but might be less flexible for institutions with strict on-premise requirements.

Innovation

AVIEW LCS

AVIEW LCS Plus integrates the analysis of lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan, representing a significant innovation in multi-disease screening. Its continuous development includes optimized UI/UX and strengthened communication functions. Viz RV/LV's innovation lies in automating a critical measurement for PE risk stratification and integrating it into a care coordination platform, but AVIEW LCS's multi-disease approach appears more broadly innovative.

Support & Docs

Viz RV/LV

Viz.ai provides dedicated customer success teams, clinical and workflow specialists, and a comprehensive knowledge base with common questions and support documentation. This suggests a robust support structure. While Coreline Soft likely offers support, specific details about their support resources and documentation are not as readily available or detailed in the provided information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature AVIEW LCS Viz RV/LV
Name AVIEW LCS Viz RV/LV
Company Coreline Soft Co. Viz.ai
Tagline AI-Powered Lung Cancer Screening & Cardiopulmonary Assessment AI-powered disease detection and intelligent care coordination
Primary Focus Detection and analysis of lung nodules, COPD, and coronary artery calcification Automated right and left ventricular diameter measurements from CTPA scans for pulmonary embolism risk stratification
Key Features (Example 1) Automated lung nodule detection and analysis Automated Right Ventricle (RV) to Left Ventricle (LV) ratio measurement
Key Features (Example 2) Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass) Provides annotated images showing ventricular measurements
Specialties Cardiology, Oncology, Pulmonology, Radiology Emergency Medicine, Pulmonology, Radiology

Videos

Demos, reviews, and walkthroughs featuring AVIEW LCS and Viz RV/LV.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

AVIEW LCS is an AI-powered solution focused on the detection and analysis of lung nodules for lung cancer screening, as well as the assessment of COPD and coronary artery calcification from a single low-dose CT scan. Viz RV/LV is an FDA-cleared AI algorithm that automates right and left ventricular diameter measurements from CTPA scans, primarily for rapid pulmonary embolism risk stratification.
AVIEW LCS is designed to perform its comprehensive cardiopulmonary assessment from a single low-dose CT scan. In contrast, Viz RV/LV specifically analyzes volumetric CTPA acquisitions to determine the RV/LV ratio for pulmonary embolism risk stratification.
AVIEW LCS offers automated lung nodule detection and analysis, Lung-RADS classification and reporting, nodule volume quantification and 3D segmentation, emphysema quantification (LAA index), and coronary artery calcification (CAC) scoring. Viz RV/LV automates the measurement of the right ventricle (RV) to left ventricle (LV) ratio and provides annotated images showing these ventricular measurements.
AVIEW LCS generates comprehensive, automated reports and integrates with PACS/RIS and third-party platforms. Viz RV/LV is a seamless component of the Viz PE Solution, which includes AI-powered alerts and notifications to care teams, a high-fidelity mobile DICOM image viewer, and a HIPAA-compliant communication platform for care coordination.
AVIEW LCS is designed for specialties such as Cardiology, Oncology, Pulmonology, and Radiology, supporting a broad cardiopulmonary assessment. Viz RV/LV primarily targets Emergency Medicine, Pulmonology, and Radiology, focusing on acute pulmonary embolism management.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.